Over the past 5 years, several immune checkpoint inhibitors (ICIs) have been approved for the treatment of metastatic renal cell carcinoma (mRCC). These include nivolumab, either alone or in combination with ipilimumab, as well as pembrolizumab and avelumab, both in combination with axitinib, a vascular endothelial growth factor-directed tyrosine kinase inhibitor. These therapies produce response rates of 40% to 60%, and median overall survival now approaches 4 years in patients with intermediate or poor risk treated with ipilimumab and nivolumab.
1,2